Novartis Halts TB Drug Production in Pakistan

Source: The News International

Jul 20, 2016

Novartis has stopped making tuberculosis drugs in Pakistan over pricing dispute, prompting fears of a health crisis due to a drug shortage.

While the Drug Regulatory Authority of Pakistan (DRAP) sets prices for critical medicines, pricing caps have not been significantly raised since 2001. Of the 18 companies licensed to make TB drugs in Pakistan, only four, including Novartis, continued manufacturing the drugs in 2016.

Last month, DRAP allowed for an 8% increase in TB drug prices under a hardship clause, which drug companies can apply for once every three years, but even DRAP's chief executive acknowledged that the price increases thus far were not enough.

Pakistan has the world's fifth highest rate of tuberculosis.

Read the The News International article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments